FOR IMMEDIATE RELEASE

MGC Diagnostics Corporation Forms
Distinguished Scientific Advisory Committee

SAINT PAUL, MN (July 14, 2016) — MGC Diagnostics Corporation (NASDAQ: MGCD), a global medical technology company, announced today it has formed a scientific advisory committee comprised of physicians and scientists to assist in providing advice and guidance on medical and scientific matters related to the Company’s business.

Todd Austin, chief executive officer of MGC Diagnostics, said, “We are honored to have these distinguished healthcare professionals that are recognized leaders within their respected field of pulmonary medicine join MGC Diagnostic’s new scientific advisory committee. Consistent with our global strategy we have assembled these leaders to leverage their vast expertise to evaluate current and future opportunities to grow the business globally.”

Distinguished members of the MGC Diagnostic Scientific Advisory Committee include:

- Jean-Benoit Martinot, MD, Head of the Pulmonology and Allergy Department CHU UCL Namur, St-Elisabeth Site, Belgium;
- Amy Olson, MD, MSPH, Assistant Professor, Department of Medicine, Division of Pulmonary, Critical Care and Sleep Medicine, National Jewish Health, Denver, Colorado;
- Felip Burgos, PhD, MsC, RPFT, RN, Associate Professor at University of Barcelona, Respiratory Diagnostic Center of Respiratory Department in Hospital Clinic, and Senior Researcher at IDIBAPS, Barcelona, Spain;
- Charles G. Irvin, Ph.D, Associate Dean for Faculty College of Medicine, Vice Chairman for Research, Department of Medicine, Professor of Medicine Molecular Physiology and Biophysics, College of Medicine University of Vermont, Burlington, Vermont; and
- Bruce Johnson, Ph.D., Professor of Medicine, Physiology and Biomedical Engineering, Department of Medicine, Division of Cardiovascular Diseases, Preventative, Occupational and Aerospace Medicine, Mayo Clinic, Rochester Minnesota.

Mr. Austin concluded, “We are firmly committed to providing our customers with a portfolio of state-of-the-art respiratory diagnostic products. With the creation of our scientific advisory committee, the Company, as well as its customers, will benefit greatly from the expertise and guidance of this outstanding team of cardiorespiratory professionals. We look forward to their contributions.”
About MGC Diagnostics

MGC Diagnostics Corporation (NASDAQ: MGCD), is a global medical technology company dedicated to cardiorespiratory health solutions. The Company, through its Medical Graphics Corporation and Medisoft SA subsidiaries, develops, manufactures and markets non-invasive diagnostic systems. This portfolio of products provides solutions for disease detection, integrated care, and wellness across the spectrum of cardiorespiratory healthcare. The Company’s products are sold internationally through distributors and in the United States through a direct sales force targeting heart and lung specialists located in hospitals, university-based medical centers, medical clinics, physicians’ offices, pharmaceutical companies, medical device manufacturers, and clinical research organizations (CROs). For more information about MGC Diagnostics, visit www.mgcdiagnostics.com.

Cautionary Statement Regarding Forward Looking Statements

From time to time, in reports filed with the Securities and Exchange Commission, in press releases, and in other communications to shareholders or the investing public, MGC Diagnostics Corporation may make forward-looking statements concerning possible or anticipated future financial performance, business activities or plans that include the words “believes,” “expects,” “anticipates,” “intends” or similar expressions. For these forward-looking statements, the Company claims the protection of the safe harbor for forward-looking statements contained in federal securities laws. These forward-looking statements are subject to a number of factors, risks and uncertainties, including those disclosed in our periodic filings with the SEC, that could cause actual performance, activities or plans after the date the statements are made to differ significantly from those indicated in the forward-looking statements. For a list of these factors, see the sections entitled “Risk Factors” and “Cautionary Note Regarding Forward Looking Statements,” in the Company’s Form 10-K for the year ended October 31, 2015, and any updates in subsequent filings on Form 10-Q or Form 8-K under the Securities Exchange Act of 1934.

Contacts

<table>
<thead>
<tr>
<th>Company</th>
<th>Investors</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wesley W. Winnekins</td>
<td>Joe Dorame, Robert Blum, Joe Diaz</td>
</tr>
<tr>
<td>Chief Financial Officer</td>
<td>Lytham Partners, LLC</td>
</tr>
<tr>
<td>MGC Diagnostics Corporation</td>
<td>(602) 889-9700</td>
</tr>
<tr>
<td>(651) 484-4874</td>
<td><a href="mailto:mgcd@lythampartners.com">mgcd@lythampartners.com</a></td>
</tr>
</tbody>
</table>

###